Preclinical development of an IgA replacement therapy for CVID patients
Official title: Preclinical Development of LCTG-001, a Human Secretory IgA Replacement Therapy for CVID Patients
Funded at Lactiga Us INC. · NIH-11532351 · Data updated 2026-11-12
A new IgA-dominant nasal therapy is being developed to help people with CVID reduce infections in the airways.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lactiga Us INC. NIH-funded |
| Lab location | 1 site (North Brunswick, United States) |
| Project start | September 10, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $969,219 |
| NIH project number | 4R42AI188865-02 |
| Project ID | NIH-11532351 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with CVID or similar humoral immunodeficiencies who experience recurrent airway infections and may benefit from enhanced mucosal immunity in the nose and airways.
✕Less likely to help
Patients without CVID or similar mucosal immune deficiencies may not experience direct benefits from this therapy.
What this research studies
This project focuses on a preclinical development of LCTG-001, a human IgA replacement designed to reach the respiratory tract where CVID patients commonly suffer infections. Researchers will optimize the formulation and delivery method to improve immunity at the nasal and respiratory surfaces. The effort aims to bridge current IgG-only therapies by addressing mucosal protection, with studies likely in lab models and human-derived samples to support future clinical testing.
Why it matters
Potential benefit: If successful, this therapy could lower respiratory infections in CVID patients by providing better mucosal immune protection.
How similar studies have gone: Previous mucosal antibody therapies have shown potential, but this approach explores a novel IgA-based replacement for CVID.
Where this research is happening
-
Lactiga Us INC.
North Brunswick, United States Active
Researchers
- Principal investigator: Mane, Viraj Pramod — Lactiga Us INC.
- Study coordinator: Mane, Viraj Pramod
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.